Capricor Therapeutics, Inc. - Common Stock (CAPR)
6.3400
-0.6300 (-9.04%)
NASDAQ · Last Trade: May 10th, 1:31 PM EDT
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · May 9, 2025

A strong jobs report and a temporary settlement of the port strike lifted stocks but inflation and earnings data could set investors up for more volatility
Via MarketBeat · October 5, 2024

Capricor Therapeutics Inc. (NASDAQ: CAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like iomyopathy
Via MarketBeat · September 30, 2024